Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with cisplatin-based induction chemotherapy in EBV-positive nasopharyngeal carcinoma
DRKS00027098Phase 2Recruiting
- Sponsor
- German Society for Pediatric Oncology and Hematology
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in nasopharyngeal carcinoma (NPC) (2 cohorts), sponsored by German Society for Pediatric Oncology and Hematology. Started Oct 2022; status: recruiting.
02
Drugs
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on DRKS00027098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00027098.